Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by Barclays PLC
Barclays PLC increased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 294.2% during ...
Pharmaceutical Technology9h
EDP-235 by Enanta Pharmaceuticals for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
EDP-235 is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).
bovnews4d
Enanta Pharmaceuticals Inc (ENTA) Stock: Surpassing Expectations in the Market
Enanta Pharmaceuticals Inc (ENTA) stock saw a decline, ending the day at $5.75 which represents a decrease of $-0.10 or -1.71% from the prior close of $5.85. The stock opened at $6 and touched a low ...